Microdosing
Microdosing involves the regular consumption of sub-hallucinogenic doses of psychedelics, primarily for cognitive enhancement and emotional wellbeing. Although popularised through anecdotal reports, rigorous scientific evidence on its effects is still limited, pointing to a critical need for further research in this emerging field.
Key Insights
- 1
Microdosing has gained popularity, particularly among young professionals, for perceived benefits in mental health and cognitive performance.
- 2
Self-reported data indicates that microdosing may be associated with lower prevalence of substance use disorders and anxiety among users.
- 3
Preliminary studies suggest microdosing may significantly impact symptoms of ADHD, offering a potential alternative to conventional medications.
- 4
Current research highlights the need for controlled clinical trials to validate the anecdotal benefits and safety of microdosing practices.
- 5
The placebo effect may play a significant role in reported outcomes of microdosing, necessitating further investigation.
What is Microdosing?
Microdosing refers to the use of low doses of psychedelic substances, typically below the threshold of perceptual effects, administered over multiple sessions with the intention of enhancing cognitive and emotional processes.
The most commonly reported substances used in microdosing are LSD and psilocybin, which are often taken on a specific schedule, such as one day on followed by two days off.
Anecdotal reports suggest benefits such as improved mental wellbeing, increased focus, and enhanced creativity; however, these claims require substantiation through scientifically rigorous methodologies.
Lack of robust clinical trials has resulted in microdosing being predominantly studied through self-reported measures, such as surveys, raising concerns about the reliability of the findings.
Current Treatments
Standard treatments for conditions like ADHD and anxiety currently include pharmacological approaches such as stimulants and SSRIs, along with behavioural therapies. These interventions, while effective, may not work for all individuals and can present side effects.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Microdosing.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| LSD Evidence primarily derived from self-reported surveys, with few clinical studies completed. | Medium | Moderate | Inconsistent |
| Psilocybin Similar to LSD, relies on self-reported outcomes with limited controlled studies thus far. | Medium | Moderate | Inconsistent |
LSD and Microdosing
LSD is known for its profound psychological effects, even at microdose levels. Users report enhanced cognitive flexibility, improved mood, and heightened creativity, although scientific validation of these claims is sparse. Preliminary findings suggest microdosing LSD may facilitate neural plasticity, which could have implications for cognitive enhancement in daily activities.
Psilocybin and Microdosing
Microdoses of psilocybin may assist in emotional regulation and cognitive improvement, according to anecdotal accounts. Early observational studies indicate that psilocybin could help alleviate symptoms related to anxiety and depression, potentially shifting the neurochemical balance towards a more positive emotional state, yet the need for controlled trials remains critical to ascertain these effects.
Clinical Outlook
The future of psychedelic treatments such as microdosing looks promising as more rigorous clinical trials are initiated, particularly those focused on specific psychological disorders. Advances in understanding the neurobiological mechanisms underlying microdosing could lead to innovative therapeutic strategies tailored to individual needs.
Industrial Landscape
Key players in the microdosing space include Woke Pharmaceuticals, which is developing novel psychedelic compounds, and MindBio Therapeutics, conducting clinical research on microdosing for various mental health conditions. Notable researchers like Vince Polito from Macquarie University are also contributing to the scientific exploration of microdosing effects.
Quick Indicators
Organisations
Search →National Institute on Drug Abuse (NIDA)
U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.
Optimi Health
Canadian GMP-certified manufacturer of pharmaceutical-grade psilocybin and MDMA, licensed by Health Canada. Optimi's facility in Princeton, British Columbia is one of the largest legal psilocybin production operations in North America. Supplies clinical trial material to researchers in Australia, Israel, and Canada.
MycoMedica Life Sciences
MycoMedica Life Sciences PBC is a public benefit corporation developing low-dose psilocybin medicines for psychiatric and neurological disorders. Their lead candidate MLS101 is in Phase 1 clinical development, with PMDD as the lead indication and OUD and OCD as additional targets. Based in Shelton, Washington.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
University of Auckland
The University of Auckland’s psychedelic therapy research programme centres on translating psychedelic science into clinically relevant mental health research. Led by Professor Suresh Muthukumaraswamy and colleagues, the programme has focused especially on LSD microdosing, with work examining effects on mood, cognition, brain function, and potential therapeutic use in conditions where current treatments remain inadequate. The university’s page frames this as a broader effort to explore psychedelic therapies for mental health, while university reporting shows the programme was seeded by philanthropic funding, later supported by the Health Research Council of New Zealand, and developed into a recognised research pathway within the institution. A key part of this work has involved microdosing trials conducted in collaboration with MindBio Therapeutics. University reporting states that MindBio provided commercial backing for the LSD microdosing research, including work that moved from healthy volunteer studies toward patient populations such as people with major depressive disorder. More recent Auckland-linked studies also show the programme expanding into other targeted applications, including late stage cancer care and menstrual health related questions, which suggests a research platform that is both mechanistic and clinically exploratory. In that sense, Auckland has become one of the more visible academic centres testing whether repeated low dose LSD can be developed into scalable, lower intensity psychedelic interventions.
MindBio Therapeutics
MindBio Therapeutics is a clinical-stage biotechnology company developing MB22001, a proprietary titratable form of LSD designed for take-home microdosing. The company's Phase 2B trials in major depressive disorder and advanced-stage cancer distress have reported strong antidepressant effects, with Phase 2a data showing a 72% reduction in depressive symptoms and 58% remission at six months. MindBio is listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange.
Yale University
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
HHC Research Open Competition
The Hartford HealthCare (HHC) Research Open Competition is an internal pilot grant program run by Hartford HealthCare — a large non-profit integrated health system in Connecticut — to fund investigator-initiated research at its affiliated institutions. Through this program, HHC supports a Phase I double-blind psilocybin microdosing trial at its Olin Neuropsychiatry Research Center in Hartford, investigating effects on cognition, mood and quality of life.
National Council of Scientific and Technical Research, Argentina
The National Council of Scientific and Technical Research (CONICET; Consejo Nacional de Investigaciones Científicas y Técnicas) is Argentina’s principal government agency for promoting science and technology, funding over 11,000 researchers and 10,000 doctoral students across a nationwide network of research institutes and centres. CONICET supported the NATMICRO study, a naturalistic observational investigation of the psychological and cognitive effects of self-administered psilocybin microdosing conducted in Argentina.
National University of Natural Medicine
The National University of Natural Medicine (NUNM) is a Portland, Oregon-based accredited institution offering graduate programmes in naturopathic medicine, integrative medicine, and classical Chinese medicine, with a research focus on evidence-based natural health approaches. NUNM co-sponsored the Optimizing Microdosing and Meditation (OMM) trial, studying whether combining psilocybin microdosing with structured mindfulness meditation practice produces synergistic improvements in psychological wellbeing.
People
Search →Federico Cavanna
Researcher in psychedelic science / neuroscientific researcher (exact current title not confidently verified)
He is a coauthor on multiple widely cited studies on psilocybin microdosing, DMT, and psychedelic use, helping characterize subjective, behavioral, and cognitive effects of psychedelics.
Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Aaron Klaiber
Doctoral researcher at the University of Basel
He appears as an author on multiple controlled human psychedelic studies spanning DMT, mescaline, MDMA, LSD, and psilocybin, suggesting a substantial role in contemporary psychopharmacology research.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
Philippe Lucas
Director, Research and Safe Access at MAPS
He is a prominent Canadian psychedelic and cannabis researcher whose work has helped establish early evidence on ayahuasca-assisted therapy, psychedelic survey research, and harm-reduction policy.
Anna Forsyth
Doctoral researcher / researcher at the University of Auckland
She is an author on multiple clinical studies of LSD microdosing in depression and related psychedelic psychiatry work, contributing to early human evidence on efficacy, tolerability, and mechanism.
Frederick Sundram
Associate Professor and Deputy Head of the Department of Psychological Medicine at the University of Auckland
He is a psychiatrist and clinical researcher contributing to psychedelic and novel-antidepressant studies, including LSD microdosing and ketamine/depression research.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Laura Alethia de la Fuente
Postdoctoral researcher in neuroscience at CONICET / Instituto de Física de Buenos Aires (IFIBA-UBA)
She co-authored several notable human psychedelic studies on psilocybin microdosing, DMT, and acute psilocybin effects, contributing both behavioral and neurophysiological evidence in the field.
Connected Evidence
The latest clinical data and verified academic findings associated with Microdosing.